Skip to main content
OpenTrials
Completed

NCT Number: NCT05592613

Next Generation Ingestible Sensors for Medication Adherence Measurement

This study will investigate the use of a next-generation Reader as part of a digital pill system (DPS; ID-Cap System) to measure adherence to both antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) in people living with HIV (PLWH) and HIV-negative individuals, respectively. During the first (non-human subjects) component of this study, we developed a wrist-borne Reader according to design specifications and preferences shared by DPS users from our previous studies. Early bench testing by etectRx (manufacturer of the ID-Cap System) demonstrated that the wrist-borne version of the Reader acquires signal from the digital pill. This study will therefore evaluate the usability of and user response to a wrist-borne Reader component of the DPS among PLWH on ART and HIV-negative individuals on PrEP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infection Adherence, Medication Adherence, Treatment Antiretroviral Therapy Behavior Blood-Borne Infections Communicable Diseases Genital Diseases HIV Infections Health Behavior Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Medication Adherence Patient Acceptance of Health Care Patient Compliance Pre-exposure Prophylaxis RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Treatment Adherence and Compliance Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Fenway Health

Boston, Massachusetts, 02215, United States

About this study

This is a single-arm, observational trial (N=30), which will enroll N=15 people living with HIV (PLWH) using Biktarvy as antiretroviral therapy (ART) and N=15 HIV-negative individuals using Truvada as pre-exposure prophylaxis (PrEP). Potential participants will be approached and pre-screened. Those who meet pre-screening criteria will attend a Screening Visit (Visit 1), where the informed consent process will be conducted and eligibility will be confirmed. Eligible participants will attend a total of 3 study visits: the Screening Visit (Visit 1), Enrollment Visit (Visit 2), and Month 1 Visit (Visit 3). Participants will take one digital pill per day (Biktarvy as ART or Truvada as PrEP) for 30 days total, while using the next-generation Reader with a digital pill system, the ID-Cap System. Timeline followback discussions will be conducted at the Month 1 Visit to understand the context of any nonadherence detected by the digital pill system. Qualitative user experience exit interviews, quantitative assessments, dried blood spots (DBS), and pill counts of unused medication will also be conducted at the Month 1 Visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PrEP Participants:
  • Age 18 or older
  • HIV negative
  • Prescribed and currently taking Truvada for PrEP for at least 30 days
  • Qualifying labs for PrEP (Cr clearance in past 6 months, HBV vaccination, liver function tests)
  • Owns a smartphone with Android or iOS
  • ART Participants:
  • Age 18 or older
  • Diagnosed with HIV
  • Prescribed and taking Biktarvy for at least 6 months
  • Undetectable viral load during prior 6 months
  • Owns a smartphone with Android or iOS

Exclusion criteria

  • PrEP Participants:
  • Does not speak English
  • History of Crohn's disease or ulcerative colitis
  • History of gastric bypass or bowel stricture
  • History of GI malignancy or radiation to abdomen
  • Allergy to gelatin, silver, or zinc
  • Implanted cardiac device, nerve stimulator, or drug infusion pump
  • Not willing to operate DPS
  • ART Participants:
  • Does not speak English
  • History of Crohn's disease or ulcerative colitis
  • History of gastric bypass or bowel stricture
  • History of GI malignancy or radiation to abdomen
  • Allergy to gelatin, silver, or zinc
  • Implanted cardiac device, nerve stimulator, or drug infusion pump
  • Not willing to operate DPS

Treatment and study plan

Next-generation Reader and ID-Cap System

Device

The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.

Other names: Digital pill system

Truvada for pre-exposure prophylaxis (PrEP)

Drug

Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.

Biktarvy for antiretroviral therapy (ART)

Drug

Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.

Primary outcomes

  1. Feasibility of Next-Generation ID-Cap System to Measure PrEP/ART Adherence

    Time frame: Month 1 study visit

    Participants' engagement with the digital pill system (DPS) -- the next-generation ID-Cap System -- will be measured over the 30-day study period. The percentages for the total expected ingestions recorded by the DPS each month will be compared to adherence detected by the DPS.

  2. Correlation of PrEP/ART Adherence with DBS Concentrations and Pill Counts

    Time frame: Month 1 study visit

    Correlation of PrEP/ART adherence patterns, as detected by the next-generation ID-Cap System, with tenofovir diphosphate concentrations in dried blood spots (DBS) and pill counts of unused digital pills following the 30-day study period.

  3. Acceptability of Next-Generation ID-Cap System, via System Usability Scale

    Time frame: Month 1 study visit

    Acceptability will be measured via the System Usability Scale (SUS). The SUS is a 10-item measure of perceived usability of a technological system, scored on a 5-point Likert scale (1: strongly disagree, 5: strongly agree), with higher scores indicating greater perceived usability. A mean score of >68 will be used to indicate that the technology is acceptable.

  4. Acceptability of Next-Generation ID-Cap System, via Qualitative Interviews

    Time frame: Month 1 study visit

    Acceptability will be evaluated via qualitative interviews exploring participants' lived experiences operating the next-generation ID-Cap system and suggestions for improving the design of the technology.

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • The Fenway Institute

Registry information

Official study title

ID Cap System: Next Generation Ingestible Sensors for Medication Adherence Measurement

Acronym: NextGen

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 24, 2022
Registry last updated
Sep 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.